You are here

Gilead Sciences reports almost US$900m in Q3 remdesivir sales

nz_gilead_291036.jpg
Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharma company Gilead Sciences by nearly US$900 million, according to results released Wednesday by the drugmaker.

[NEW YORK] Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharma company Gilead Sciences by nearly US$900 million, according to results released Wednesday by the drugmaker.

The medication, sold under the brand name Veklury, which was originally developed to...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes